Pneumococcal Conjugate Vaccine Impact Study

PI: Anthony Scott
Funding: Wellcome Trust and GAVI Alliance

Using a passive-surveillance system established in 2003 at the Kilifi Health and Demographic Surveillance System, in Kilifi, Kenya, this project is a Phase IV, before-after study, examining the population impact of the 10-valent Pneumococcal Conjugate Vaccine (PCV), which was introduced into the Kenyan childhood immunization system in January 2011. The project examines both direct and indirect vaccine effects on the primary endpoint – invasive pneumococcal disease, as well as serotype replacement disease. It has reported the initial impact of the programme on pneumococcal carriage – indicating a significant effect on transmission of vaccine serotypes. The study will also report on the wider public health end-point of radiologicaly-confirmed pneumonia. The study is a collaboration with the Unit for Vaccines and Immunisation at the Ministry of Health in Kenya and also with partners at Johns Hopkins School of Public Health.

> More information

Back